Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.
Medscape Medical News
Most patients with advanced non–small cell lung cancer (NSCLC) have tumors with actionable mutations, but two thirds of them are not receiving targeted therapy owing to gaps in clinical practice.
Medscape Medical News